JANUX THERAPEUTICS INC's ticker is JANX and the CUSIP is 47103J105. A total of 121 filers reported holding JANUX THERAPEUTICS INC in Q1 2024. The put-call ratio across all filers is 1.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $58,697,692 | +290.3% | 1,401,234 | +250.8% | 0.00% | +200.0% |
| Q1 2024 | $15,039,933 | +303.3% | 399,467 | +14.9% | 0.00% | – |
| Q4 2023 | $3,729,587 | +11.6% | 347,585 | +4.8% | 0.00% | – |
| Q3 2023 | $3,342,236 | -15.3% | 331,571 | -0.3% | 0.00% | – |
| Q2 2023 | $3,947,843 | +9.3% | 332,590 | +11.4% | 0.00% | – |
| Q1 2023 | $3,613,411 | -51.5% | 298,629 | -47.3% | 0.00% | – |
| Q4 2022 | $7,457,118 | +108.5% | 566,220 | +114.3% | 0.00% | – |
| Q3 2022 | $3,577,000 | +10.9% | 264,207 | +0.1% | 0.00% | – |
| Q2 2022 | $3,224,000 | -7.1% | 264,022 | +9.1% | 0.00% | – |
| Q1 2022 | $3,470,000 | -16.9% | 241,998 | +14.4% | 0.00% | – |
| Q4 2021 | $4,174,000 | +10.5% | 211,566 | +21.1% | 0.00% | – |
| Q3 2021 | $3,778,000 | – | 174,644 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 9,165,652 | $383,949,162 | 5.08% |
| Logos Global Management LP | 750,000 | $31,417,500 | 2.55% |
| Cormorant Asset Management, LP | 1,050,000 | $43,984,500 | 2.54% |
| Paradigm Biocapital Advisors LP | 1,564,452 | $65,534,894 | 2.51% |
| Orbimed Advisors | 2,979,828 | $124,824,995 | 2.46% |
| Vestal Point Capital, LP | 725,000 | $30,370,250 | 2.26% |
| EcoR1 Capital, LLC | 1,469,818 | $61,570,676 | 1.88% |
| Avidity Partners Management LP | 840,219 | $35,196,774 | 1.50% |
| Ratan Capital Management LP | 105,757 | $4,430,160 | 1.34% |
| STEMPOINT CAPITAL LP | 92,949 | $3,893,634 | 1.14% |